Antidote Technologies' Report on Survey of 4,000 Patients Reveals How to Increase Diversity in Clinical Research

Share Article

Findings provide insights into reducing barriers in clinical trial recruitment for underrepresented populations

News Image
These survey findings suggest that catering study design, outreach approach, and logistical support to specific populations will reduce barriers to participation and result in drugs that are effective for all those in need.

Antidote Technologies today announced the findings from a recent survey of 4,000 patients and caregivers about their attitudes towards clinical research. The survey was developed and distributed in partnership with Scorr Marketing and eight advocacy organizations: Allergy & Asthma Network, American Kidney Fund, GO2 Foundation for Lung Cancer, Healthline, JDRF, Lupus Research Alliance, Melanoma Research Alliance, and Multiple Sclerosis Association of America. Among the findings in the study was a clear distinction in the motivation between white individuals and people of color, regardless of condition, when considering volunteering for research.

People of color have traditionally been underrepresented in clinical research. Nearly 40% of the population in the United States are racial and ethnic minorities, but estimated rates of research participation for these groups range from 2% to 16%.[1,2] For example, Latinos make up 18% of the American population, but just 1% of the clinical trial participant population.[2] A lack of trust stemming from historical events such as the Tuskegee Study has been cited as a major barrier to participation. In order to develop drugs that are effective for everyone living with a particular condition, diverse participation in clinical trials is needed.

The survey revealed several factors that affect the participation of people of color, including trial type preferences, motivations for and barriers to taking part in a clinical trial, and logistical factors. Highlights include:

  • Trial type: While white individuals were more likely to take part in a trial overall, non-white individuals were more likely to take part in an observational trial (83% vs. 79%).
  • Engagement: Hispanic and non-white individuals were more interested in talking with those responsible for the research than their non-Hispanic, white peers were (83% vs. 74%). And, people of color were also more interested in hearing from peers who have participated in research (77% vs. 73%).
  • Motivation: The segment of non-white individuals who had taken part in a trial in the past were least likely to say that following their doctor’s recommendation was a major factor in their trial participation (33% vs. 25%).
  • Logistics: Non-white individuals were significantly more interested in home visits than were white individuals (59% vs. 38%). The same was true for Hispanic versus non-Hispanic individuals (62% vs. 40%).
  • Financial incentives: Hispanic and non-white individuals rated financial factors, such as payment, reimbursement, and receipt of free or reduced care, as significantly more important than did their white, non-Hispanic peers.

“I often hear from Antidote’s patient advocacy group partners about the need to even the scales in terms of research diversity,” said Lindsey Wahlstrom-Edwards, Head of Partnerships at Antidote. “These survey findings suggest that catering study design, outreach approach, and logistical support to specific populations will reduce barriers to participation and result in drugs that are effective for all those in need. This is especially critical in conditions that disproportionately affect communities of color, like lupus, asthma, diabetes, and Alzheimer’s disease.”

For details on the findings of this survey, please download Antidote’s whitepapers here: http://www.antidote.me/antidote-whitepapers.

About Antidote

Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.

Media Contacts

Lisa Conroy
Director of Communications, Antidote
lisa@antidote.me
215-872-2917

Grace McElroy
Vice President, Marketing and Partnerships
grace@antidote.me
914-643-5260

References

1. U.S. Census Bureau QuickFacts: United States. (2018, July 1). Retrieved November 20, 2019, from https://www.census.gov/quickfacts/fact/table/US/PST045218.

2. DeArment, A. MedCityNews. (2019, July 8). As precision medicine grows, so does the importance of clinical trial diversity. Retrieved November 20, 2019, from https://medcitynews.com/2019/07/as-precision-medicine-grows-so-does-the-importance-of-clinical-trial-diversity/.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Conroy

Grace McElroy
@antidote_me
Follow >
Antidote.me
Like >
Visit website